

CLAIMS:

1. An isolated endostatin protein, wherein the protein has an amino acid sequence selected from the group consisting of SEQ ID NO:3 and SEQ ID NO:5.
2. The endostatin protein of Claim 1 having an amino acid sequence of SEQ ID NO:3.
3. The endostatin protein of Claim 1 having an amino acid sequence of SEQ ID NO:5.
4. The endostatin protein of Claim 1 made by a process comprising, recombinantly producing the protein of Claim 1 in a recombinant expression system, and isolating the recombinantly produced protein in its un-refolded form.
5. The endostatin protein of Claim 4, wherein the endostatin protein has an amino acid sequence of SEQ ID NO:3.
6. The endostatin protein of Claim 4, wherein the endostatin protein has an amino acid sequence of SEQ ID NO:5.
7. The endostatin protein of Claim 4, wherein the recombinant expression system is selected from the group consisting of bacterial expression systems, yeast expression systems and insect viral expression systems.
8. The endostatin protein of Claim 7, wherein the recombinant expression system is *E. coli*, *Pichia*, or baculovirus.
9. An isolated nucleic acid molecule having a sequence encoding an endostatin protein, wherein the nucleic acid sequence

5

10

15

20

25

30

18. The composition of Claim 15, wherein the composition provides a sustained release of the endostatin protein for a period of at least 8 hours.

19. The endostatin protein of Claim 15, wherein the protein is administered to an individual for the treatment of an angiogenesis-related disease.

5

20. The endostatin protein of Claim 15, wherein the angiogenesis-related disease is an angiogenesis-dependent cancer.

1004347.0110
2017.07.10